Announced Date: 2025-03-21 (March 21, 2025)
Licensor: Syneron Bio (China)
Licensee: AstraZeneca（UK）
Collaboration Object: Co-develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases.
Main Tech: Syneron Bio’ s TechSynova™ platform
.
Scope of Collaboration:
AstraZeneca will gain access to Syneron Bio’s innovative Synova™ platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases, including rare, autoimmune, and metabolic disease.
.
Deal Detail:
Upfront payment and near term payment $75 million;
Development and regulatory, Sales milestone payments up to $3.4 billion;
Total up to $3.475 billion.
Additional royalties based on net sales.
Additionally, Astra Zeneca will invest to Syneron Bio.
.
Link:
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing
